The Dilemma of Drug Policy in the United States PDF Download
Are you looking for read ebook online? Search for your book and save it on your Kindle device, PC, phones or tablets. Download The Dilemma of Drug Policy in the United States PDF full book. Access full book title The Dilemma of Drug Policy in the United States by Elaine B. Sharp. Download full books in PDF and EPUB format.
Author: Elaine B. Sharp Publisher: Addison Wesley Publishing Company ISBN: Category : Law Languages : en Pages : 214
Book Description
Some Sharp observations ... Emphasizing interrelated themes of policy failure and policy change, this book is a theoretical and conceptual examination of drug policy in the United States. It is in part a policy history, using case studies to link specific drug policies to a general theoretical framework. These cases focus primarily on three important and interesting episodes of drug policy development during the Nixon-Carter, and Reagan-Bush administrations, and the author interprets the historical significance of each period. The Dilemma of Drug Policy in the United States examines a wide array of ideas concerning incrementalism, interest groups, and symbolic politics to determine why there has been so much continuity in drug policy despite policy failure. Finally, a chapter on policy alternatives deals with the legalization debate, and critiques it from the perspective of a political scientist.
Author: Elaine B. Sharp Publisher: Addison Wesley Publishing Company ISBN: Category : Law Languages : en Pages : 214
Book Description
Some Sharp observations ... Emphasizing interrelated themes of policy failure and policy change, this book is a theoretical and conceptual examination of drug policy in the United States. It is in part a policy history, using case studies to link specific drug policies to a general theoretical framework. These cases focus primarily on three important and interesting episodes of drug policy development during the Nixon-Carter, and Reagan-Bush administrations, and the author interprets the historical significance of each period. The Dilemma of Drug Policy in the United States examines a wide array of ideas concerning incrementalism, interest groups, and symbolic politics to determine why there has been so much continuity in drug policy despite policy failure. Finally, a chapter on policy alternatives deals with the legalization debate, and critiques it from the perspective of a political scientist.
Author: United States. Commission on Marihuana and Drug Abuse Publisher: Ardent Media ISBN: 9780842272391 Category : Political Science Languages : en Pages : 510
Author: Jason Stone Publisher: IDEA ISBN: 9780972054126 Category : Political Science Languages : en Pages : 278
Book Description
The anthology is designed as a starting point for academic debate about illegal drugs. The 25 reprinted articles cover reducing harm and reduction, law enforcement, supply reduction, the European Union's drug policies, and terrorism and drugs. Each appends suggested topics for debate. They are not i
Author: United States. Congress. House. Committee on Government Reform. Subcommittee on Criminal Justice, Drug Policy, and Human Resources Publisher: ISBN: Category : Political Science Languages : en Pages : 96
Author: Jonathan P. Caulkins Publisher: Oxford University Press ISBN: 0190269197 Category : Political Science Languages : en Pages : 544
Book Description
Debate around drugs and the policies, taxes, and regulations that surround them have left citizens and officials with questions on what can be done about both illicit drugs and marijuana. The foremost public and scholarly authorities on U.S. drug policy provide a truly balanced and comprehensive overview of the subject in this bundle containing Drugs and Drug Policy: What Everyone Needs to Know and Marijuana Legalization: What Everyone Needs to Know.
Author: Bruce White Publisher: CRC Press ISBN: 1000572552 Category : Business & Economics Languages : en Pages : 352
Book Description
Weigh pivotal healthcare ethics, law, and public policy issues that resulted in tipping-point legal actions Weighing the ethical considerations in healthcare and drug issues can be emotionally difficult and mentally challenging. Drugs, Ethics, and Quality of Life: Cases and Materials on Ethical, Legal, and Public Policy Dilemmas in Medicine and Pharmacy Practice is a fascinating casebook that clearly discusses the most contentious ethical conflicts that resulted in legal actions. This easy-to-read text provides all sides of controversial real-life cases that provoke spirited debate while teaching the fundamentals of pharmacy law and ethics. The book is a unique exploration into the basic principles of bioethics, end of life care, and drug research. Drugs, Ethics, and Quality of Life explains in detail the concepts of ethics, quality of life, beneficence, nonmaleficence, autonomy, and justice. Recent cases provide illuminating backdrops for the exploration of these concepts, making them easily understood. A special introduction includes important information about ethics and the pharmaceutical code of ethics. Two appendixes provide further opportunities for discussion and the examination of law and decisions, and resources about drug use decisions and situations. This thought-provoking textbook plainly shows the crucial role ethics plays in today’s society. Ethical topics explored in Drugs, Ethics, and Quality of Life includes legal cases on: tobacco COX-2 inhibitors medical marijuana the “morning after” pill and other emergency contraceptives pain medications and palliative care drugs physician-assisted suicide drug use in medically futile situations gene therapy Drugs, Ethics, and Quality of Life is valuable, insightful reading as well as a good adjunct text for pharmacy students, pharmacists, medical students, physicians, bio
Author: Marcia Angell Publisher: Random House Trade Paperbacks ISBN: 0375760946 Category : Business & Economics Languages : en Pages : 354
Book Description
During her two decades at The New England Journal of Medicine, Dr. Marcia Angell had a front-row seat on the appalling spectacle of the pharmaceutical industry. She watched drug companies stray from their original mission of discovering and manufacturing useful drugs and instead become vast marketing machines with unprecedented control over their own fortunes. She saw them gain nearly limitless influence over medical research, education, and how doctors do their jobs. She sympathized as the American public, particularly the elderly, struggled and increasingly failed to meet spiraling prescription drug prices. Now, in this bold, hard-hitting new book, Dr. Angell exposes the shocking truth of what the pharmaceutical industry has become–and argues for essential, long-overdue change. Currently Americans spend a staggering $200 billion each year on prescription drugs. As Dr. Angell powerfully demonstrates, claims that high drug prices are necessary to fund research and development are unfounded: The truth is that drug companies funnel the bulk of their resources into the marketing of products of dubious benefit. Meanwhile, as profits soar, the companies brazenly use their wealth and power to push their agenda through Congress, the FDA, and academic medical centers. Zeroing in on hugely successful drugs like AZT (the first drug to treat HIV/AIDS), Taxol (the best-selling cancer drug in history), and the blockbuster allergy drug Claritin, Dr. Angell demonstrates exactly how new products are brought to market. Drug companies, she shows, routinely rely on publicly funded institutions for their basic research; they rig clinical trials to make their products look better than they are; and they use their legions of lawyers to stretch out government-granted exclusive marketing rights for years. They also flood the market with copycat drugs that cost a lot more than the drugs they mimic but are no more effective. The American pharmaceutical industry needs to be saved, mainly from itself, and Dr. Angell proposes a program of vital reforms, which includes restoring impartiality to clinical research and severing the ties between drug companies and medical education. Written with fierce passion and substantiated with in-depth research, The Truth About the Drug Companies is a searing indictment of an industry that has spun out of control.
Author: Horace A. Bartilow Publisher: UNC Press Books ISBN: 1469652560 Category : Political Science Languages : en Pages : 321
Book Description
In this book, Horace Bartilow develops a theory of embedded corporatism to explain the U.S. government's war on drugs. Stemming from President Richard Nixon's 1971 call for an international approach to this "war," U.S. drug enforcement policy has persisted with few changes to the present day, despite widespread criticism of its effectiveness and of its unequal effects on hundreds of millions of people across the Americas. While researchers consistently emphasize the role of race in U.S. drug enforcement, Bartilow's empirical analysis highlights the class dimension of the drug war and the immense power that American corporations wield within the regime. Drawing on qualitative case study methods, declassified U.S. government documents, and advanced econometric estimators that analyze cross-national data, Bartilow demonstrates how corporate power is projected and embedded—in lobbying, financing of federal elections, funding of policy think tanks, and interlocks with the federal government and the military. Embedded corporatism, he explains, creates the conditions by which interests of state and nonstate members of the regime converge to promote capital accumulation. The subsequent human rights repression, illiberal democratic governments, antiworker practices, and widening income inequality throughout the Americas, Bartilow argues, are the pathological policy outcomes of embedded corporatism in drug enforcement.
Author: National Academies of Sciences, Engineering, and Medicine Publisher: National Academies Press ISBN: 0309486483 Category : Medical Languages : en Pages : 175
Book Description
The opioid crisis in the United States has come about because of excessive use of these drugs for both legal and illicit purposes and unprecedented levels of consequent opioid use disorder (OUD). More than 2 million people in the United States are estimated to have OUD, which is caused by prolonged use of prescription opioids, heroin, or other illicit opioids. OUD is a life-threatening condition associated with a 20-fold greater risk of early death due to overdose, infectious diseases, trauma, and suicide. Mortality related to OUD continues to escalate as this public health crisis gathers momentum across the country, with opioid overdoses killing more than 47,000 people in 2017 in the United States. Efforts to date have made no real headway in stemming this crisis, in large part because tools that already existâ€"like evidence-based medicationsâ€"are not being deployed to maximum impact. To support the dissemination of accurate patient-focused information about treatments for addiction, and to help provide scientific solutions to the current opioid crisis, this report studies the evidence base on medication assisted treatment (MAT) for OUD. It examines available evidence on the range of parameters and circumstances in which MAT can be effectively delivered and identifies additional research needed.
Author: Elaine B. Sharp
Author: Elaine B. Sharp
Author: United States. Commission on Marihuana and Drug Abuse
Author: Jason Stone
Author: United States. Congress. House. Committee on Government Reform. Subcommittee on Criminal Justice, Drug Policy, and Human Resources
Author: Jonathan P. Caulkins
Author: Melvyn B. Krauss
Author: Bruce White
Author: Marcia Angell
Author: Horace A. Bartilow
Author: National Academies of Sciences, Engineering, and Medicine